- Home
- PAVM vs NCNA Comparison
PAVM vs NCNA Comparison
Compare PAVM & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- NCNA
- Stock Information
- Founded
- PAVM 2014
- NCNA 1997
- Country
- PAVM United States
- NCNA United Kingdom
- Employees
- PAVM N/A
- NCNA N/A
- Industry
- PAVM Medical/Dental Instruments
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- NCNA Health Care
- Exchange
- PAVM Nasdaq
- NCNA Nasdaq
- Market Cap
- PAVM 8.0M
- NCNA 6.6M
- IPO Year
- PAVM 2016
- NCNA 2017
- Fundamental
- Price
- PAVM $0.45
- NCNA $2.87
- Analyst Decision
- PAVM Strong Buy
- NCNA
- Analyst Count
- PAVM 1
- NCNA 0
- Target Price
- PAVM $19.00
- NCNA N/A
- AVG Volume (30 Days)
- PAVM 376.9K
- NCNA 483.1K
- Earning Date
- PAVM 08-14-2025
- NCNA 08-20-2025
- Dividend Yield
- PAVM N/A
- NCNA N/A
- EPS Growth
- PAVM N/A
- NCNA N/A
- EPS
- PAVM 0.83
- NCNA N/A
- Revenue
- PAVM $1,020,000.00
- NCNA N/A
- Revenue This Year
- PAVM N/A
- NCNA N/A
- Revenue Next Year
- PAVM $455.63
- NCNA N/A
- P/E Ratio
- PAVM $0.54
- NCNA N/A
- Revenue Growth
- PAVM N/A
- NCNA N/A
- 52 Week Low
- PAVM $0.30
- NCNA $2.78
- 52 Week High
- PAVM $1.90
- NCNA $1,650.00
- Technical
- Relative Strength Index (RSI)
- PAVM 43.12
- NCNA 29.04
- Support Level
- PAVM $0.42
- NCNA $2.78
- Resistance Level
- PAVM $0.49
- NCNA $3.60
- Average True Range (ATR)
- PAVM 0.04
- NCNA 0.28
- MACD
- PAVM 0.00
- NCNA 0.32
- Stochastic Oscillator
- PAVM 30.87
- NCNA 7.20
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.